Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECT 2: Infergen plus ribavirin in HCV nonresponders
NCT00086541Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jun 2004
- Modality
- PEGylated Peptides, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of Peginterferon alfacon-1 in hepatitis C (HCV), sponsored by Valeant Pharmaceuticals. Started Jun 2004; status: completed.
02
Drugs
Peginterferon alfacon-1
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00086541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086541.